Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2023-09-01 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
金陵药业股份有限公司最近一年的财务报告及其审计报告以及最近一期的财务报告
Regulatory Filings
2023-09-01 Chinese
金陵药业股份有限公司关于向特定对象发行股票的募集说明书等申请文件财务数据更新的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement (578 characters) regarding an update to financial data in application documents for a specific share issuance to targeted investors. It references prior disclosures including a half-year report and a revised prospectus, but does not contain actual financial statements or detailed financial data itself. It also mentions ongoing regulatory review by the Shenzhen Stock Exchange and the China Securities Regulatory Commission. The document serves as a notification about the update and the status of the approval process rather than the report or prospectus itself. Therefore, it fits best as a Capital/Financing Update (CAP) since it relates to a specific financing activity (targeted share issuance) and updates on that process.
2023-09-01 Chinese
中信证券股份有限公司关于金陵药业股份有限公司2023年度向特定对象发行A股股票之上市保荐书（修订稿）
Capital/Financing Update Classification · 95% confidence The document is titled as a "上市保荐书" (Listing Sponsorship Letter) related to a 2023 specific object issuance of A shares by Jinling Pharmaceutical Company Limited. It contains detailed information about the issuer, the issuance plan, financial data, risk factors, issuance terms, pricing, lock-up periods, and the roles of the sponsoring institution and representatives. The document is a comprehensive formal filing related to a capital raising event through a specific share issuance. It is not a simple announcement or a brief summary but a detailed official document supporting the issuance and listing process. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document is not an Annual Report, Earnings Release, or any other category. Therefore, the correct classification is CAP with high confidence.
2023-09-01 Chinese
金陵药业股份有限公司第九届监事会第三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolution passed at the third meeting of the ninth Supervisory Board of Jinling Pharmaceutical Co., Ltd. It includes details about the meeting notice, attendance, voting results, and compliance with legal and regulatory requirements. The content focuses on board/management decisions, specifically related to approval of a related-party transaction. The document is short (534 characters) and is an announcement of a board meeting resolution rather than a full report or financial statement. Therefore, it fits best under the category of Board/Management Information (MANG).
2023-08-31 Chinese
金陵药业股份有限公司关于拟与关联方签署合作协议暨关联交易的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement about a proposed cooperation agreement and related party transaction between the company and an affiliated party. It includes specifics about the transaction, the parties involved, financial details, terms of the agreement, and independent directors' opinions. It is not a financial report, earnings release, or regulatory certification. It is a formal announcement of a related party transaction and cooperation agreement, which fits best under the category of Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories like capital update or management change. The document length and content confirm it is not a brief notice or a report publication announcement.
2023-08-31 Chinese
金陵药业股份有限公司第九届董事会第三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the third meeting of the ninth board of directors of Jinling Pharmaceutical Co., Ltd. It includes details about the meeting date, voting results, and appointment of a securities affairs representative. It does not contain financial statements or detailed financial performance data. The document is an official announcement related to board/management decisions and appointments, specifically about board meeting resolutions and management changes. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and it is not a report or presentation but an announcement of board decisions.
2023-08-31 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.